PARP1 and metabolic dysfunction-associated steatotic liver disease: For example, in non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), activation of PARP1 and PARP2 leads to increased fat accumulation in hepatocytes [195, 196], while PARP inhibition attenuates these pathological changes [190, 195].